EcoR1 Capital LLC Sells 167,004 Shares of Aligos Therapeutics, Inc. $ALGS

Key Points

• EcoR1 Capital LLC has reduced its stake in Aligos Therapeutics by 65.3%, now owning 88,569 shares worth approximately $731,000.
• HC Wainwright initiated coverage on Aligos Therapeutics, issuing a buy rating with a target price of $50.00.
• Aligos Therapeutics reported earnings of ($1.53) per share for the last quarter, exceeding estimates, along with revenue of $0.97 million compared to expected $0.43 million.

EcoR1 Capital LLC lowered its position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 65.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,569 shares of the company's stock after selling 167,004 shares during the quarter. EcoR1 Capital LLC owned about 1.45% of Aligos Therapeutics worth $731,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ALGS. Tower Research Capital LLC TRC lifted its position in Aligos Therapeutics by 2,073.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after acquiring an additional 622 shares in the last quarter. Northern Trust Corp purchased a new stake in Aligos Therapeutics in the 4th quarter valued at about $205,000. Golden State Wealth Management LLC increased its stake in Aligos Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after buying an additional 2,674 shares during the last quarter. Readystate Asset Management LP purchased a new stake in Aligos Therapeutics in the 1st quarter valued at about $375,000. Finally, AlphaQuest LLC purchased a new stake in Aligos Therapeutics in the 1st quarter valued at about $130,000. Institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Stock Performance

ALGS stock traded down $0.03 during midday trading on Tuesday, reaching $11.08. 17,687 shares of the company's stock traded hands, compared to its average volume of 163,179. The company has a 50-day moving average price of $8.89 and a two-hundred day moving average price of $8.17. Aligos Therapeutics, Inc. has a 52 week low of $3.76 and a 52 week high of $46.80. The firm has a market capitalization of $68.14 million, a PE ratio of -0.56 and a beta of 2.79.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.35) by $0.82. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $0.43 million. As a group, analysts predict that Aligos Therapeutics, Inc. will post -10.36 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright started coverage on shares of Aligos Therapeutics in a research note on Monday, August 18th. They set a "buy" rating and a $50.00 price target for the company. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $50.00.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).